Cracking The Code: Understanding Analyst Reviews For Biogen
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed reviews for Biogen (NASDAQ:BIIB) over the past three months, with a range of bullish to bearish sentiments. The average 12-month price target has decreased slightly to $281.45. Biogen's financial health shows positive revenue trends and strong net margins, but it trails behind industry peers in growth rate.
August 19, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen has received mixed analyst ratings, with a slight decrease in the average price target to $281.45. The company's financials show strong net margins and efficient asset use, but its growth rate is below industry averages.
The mixed analyst ratings and slight decrease in price target suggest a neutral short-term impact on Biogen's stock. While the company shows strong financial health, its growth rate is below industry averages, which may concern investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100